Clinical Trials Logo

Clinical Trial Summary

This study is looking at how Mim8 works compared to other medicines in children with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used for prevention of bleeds. Mim8 will be injected with a thin needle into the skin. The study will last for about 54-98 weeks, from screening to follow-up visit, In case the participant experiences bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05306418
Study type Interventional
Source Novo Nordisk A/S
Contact Novo Nordisk
Phone (+1) 866-867-7178
Email clinicaltrials@novonordisk.com
Status Recruiting
Phase Phase 3
Start date April 4, 2022
Completion date April 10, 2025

See also
  Status Clinical Trial Phase
Completed NCT04204408 - A Research Study Investigating Mim8 in People With Haemophilia A Phase 2